Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer-Decoding Endometrial Cancer: The Role of Molecular Profiling

Decoding Endometrial Cancer: The Role of Molecular Profiling

Video Transcription

Video Summary

The symposium emphasized that molecular profiling is essential for personalized endometrial cancer treatment. Dr. Olavaye reviewed the TCGA molecular subtypes: POLE-ultramutated, MMR-deficient (MSI-hypermutated), NSMP/copy-number low, and p53-abnormal/copy-number high. These subtypes have major prognostic and treatment implications, sometimes overriding histology, since aggressive molecular profiles can appear in low-grade tumors and vice versa. Because full sequencing is impractical for all cases, a surrogate workflow using POLE sequencing, MMR immunohistochemistry, and p53 testing is commonly used. The talk also covered HER2 signaling as an actionable target, especially in serous and some endometrial cancers, with trastuzumab and trastuzumab deruxtecan showing benefit. Finally, MMR status was highlighted as a key predictive biomarker: MMR-deficient tumors respond well to checkpoint inhibitors, while MMR-proficient tumors benefit less. Overall, the message was that precision oncology is increasingly guiding endometrial cancer care.

Keywords

endometrial cancer

molecular profiling

TCGA subtypes

MMR deficiency

precision oncology